Skip to main content
Journal of Atrial Fibrillation logoLink to Journal of Atrial Fibrillation
. 2012 Dec 16;5(4):691. doi: 10.4022/jafib.691

Atrial Remodelling : Role in Atrial Fibrillation Ablation

Herko Grubitzsch 1, Wilhelm Haverkamp 2,*
PMCID: PMC5153159  PMID: 28496795

Abstract

There have been considerable advances in understanding the relationship of atrial fibrillation (AF) and atrial remodelling suggesting that remodelling states have a significant impact on treatment results.

Therefore, we reviewed the literature about the role of atrial remodelling in AF treatment, focussing on AF ablation.

Atrial fibrillatory activity, dominant frequencies (DF), complex fractionated atrial electrograms (CFAE) as well as function, volume, and fibrosis of the – especially left – atrium are most important characteristics for electrical, contractile, and structural remodelling predicting success of AF treatment. In particular, the results of AF ablation, either using catheter-based or surgical techniques, predominantly depend on the degree of structural remodelling, namely dilatation and fibrosis of the left atrium.

The available data suggest that recognizing parameters of remodelling as predictors for AF treatment facilitates differentiation between patients who may or may not benefit from the procedure and individualization of AF treatment by adapting lesion sets, by ablating additional targets, by reducing left atrial size, or by applying extended pharmacological treatment.

Introduction

Atrial fibrillation (AF), the most frequent sustained atrial arrhythmia, whose prevalence increases with age, is known as independent risk factor for stroke, heart failure, and premature death.[16]

During the last decades progress has been made (1) in elucidating mechanisms underlying AF and (2) in developing new techniques for AF treatment. Especially catheter-based and surgical techniques for AF ablation evolved and are now increasingly used.[7,8] However, despite relatively high success rates, sinus rhythm can not be re-established in each patient and AF may persist or recur.[710]

Nowadays, we realize that AF is a progressively developing arrhythmia. AF itself - as well as many other conditions – induces numerous and multifaceted alterations in atrial myocardium which are properly referred to as atrial remodelling.[11] This process can be understood as link between initiation and perpetuation of AF.

From this perspective, we undertook a review of the literature dealing with the role of atrial remodelling in AF ablation. A selective literature search was carried out in the Medline database to identify original articles and reviews published in peer-reviewed journals between January 1995 and June 2012. The terms “atrial remodelling” and “ablation” as well as the Medical Subject Headings (MeSH) “atrial fibrillation”, “physiopathology”, “catheter ablation”, and “ablation techniques” were entered for literature search. Articles were selected on the criteria that they report on human findings of atrial remodelling in AF – preferably within clinical context – and on outcome of AF treatment in relation to parameters of atrial remodelling. The current Consensus Statement on Catheter and Surgical AF Ablation as well as American and European guidelines were also included for consideration.[1,1215]

Pathophysiological Mechanisms of AF

Trigger and Substrate

Current concepts explaining the complex pathophysiology of AF are comprehensively reviewed elsewhere.[11,16,17] In brief, the development of AF requires a trigger as well as an anatomic or functional substrate capable of both initiation and perpetuation of this arrhythmia.[18,19] Many mechanisms leading to focal ectopic generators due to abnormal impulse formation can be considered as trigger.[16] Atrial extrasystoles originating in the orificial area of pulmonary veins are typical triggers in early AF stages, whereas such sites of high-frequency activity both spread to left atrial posterior wall or other atrial regions and increase in number, later.[18,20,21] For circulating excitations perpetuating AF, formation of reentry circuits is necessary. Conditions like shortening of refractoriness, reduction of conduction velocity, inhomogeneties of impulse propagation, atrial dilatation, and tissue anisotropy serve as substrate for reentry.

Atrial Remodelling

Numerous electrical, contractile, and structural alterations of the atria occur due to AF itself (Table 1). Among these characteristic findings of atrial remodeling, shortening of atrial refractoriness, loss of atrial contractility as well as atrial dilatation and fibrosis are cornerstones of the remodelling process and crucial prerequisites for AF perpetuation respectively. Other cardiac and extra-cardiac factors, e.g. structural heart disease, heart failure, hypertension, status of the autonomic nervous system, aging etc. (examples see Table 1), similarly change properties of atrial myocardium and contribute to initiation and perpetuation of AF.

Table 1. Atrial Remodelling in Humans Due to AF and Other Factors (Examples).

Factors Electrical Remodelling Contractile Structural
AF decreased depolarizing currents (↓ICaL) [22, 23] Increase in fibrillatory rate [24] Shortened APD [22, 25, 26] Loss of rate adaptation of AERP [25] ↓atrial contractility [27, 28] ↓mean peak systolic left atrial strain rate [29] atrial dilatation [27] fibro-fatty replacement [30] fibrosis [31-33] isolated atrial amyloidosis [34]
Factors other than AF
structural heart disease decreased depolarizing currents (↓ICaL) [35] fibrosis [33, 36, 37] isolated atrial amyloidosis [34]
aging pulmonary veins arrhythmogenesis [38] atrial dilatation [39] replacement and reactive fibrosis [40] isolated atrial amyloidosis [34]
APD, action potential duration, AERP atrial effective refractory period

Structural remodelling usually occurs after months, whereas electrical and contractile Remodelling develops almost immediately after AF initiation. When AF is maintained for at least 24 h, ion channel adaptation changes the electrophysiological substrate resulting in sustained reentry and increased activity of triggers supporting AF consolidation.[11,16]

Single or multiple areas with sustained high rates – observed as dominant frequencies (DF) and complex fractionated atrial electrograms (CFAE) – may evolve due to electrical and/or structural alterations. Laboratory results suggest, that contractile remodelling goes hand in hand with electrical remodelling and that atrial dilatation during the first days of AF is primarily due to loss of atrial contractility.[41,42] On ultrastructural level, the most conspicuous finding of remodelling is interstitial fibrosis, which may become manifest as replacement fibrosis due to myocardial cell death or reactive fibrosis due to activation of profibrotic pathways.[17,43] Obviously, factors like structural heart disease, heart failure and aging can trigger fibrosis independently from AF.

It is of importance to note, that atrial remodelling does not affect the atrial myocardium homogenously. There is strong evidence for tissue anisotropy caused by inhomogenous electrophysiological alterations and/or unevenly distributed interstitial fibrosis capable to host small and large re-entrant wavelets.[36,44]

Electrical remodelling after re-establishing sinus rhythm reverses rapidly and completely, even after months to years of AF.[45] Renormalization of contractile remodelling strongly depends on AF duration. Echocardiographic studies after cardioversion demonstrated that atrial contractile dysfunction recovered completely within 24 hours of sinus rhythm when AF lasted 2 weeks, whereas recovery took more than 1 month when AF lasted more than 6 weeks.[46] Renormalization of structuralremodelling takes much more time and is possibly incomplete.[47]

Although well-defined animal experiments of short-term AF were able to demonstrate a close relation between different levels of remodelling,[41] clinical studies have failed to do so.[28,48] A high interindividual variability of different remodelling parameters, the missing correlation with AF duration, and the presence of additional patient- and disease-related factors, apparently hamper the detection of any supposed relationship.

Atrial Remodelling and AF Treatment

The huge variety of demographic, cardiac, and extra-cardiac factors causing or contributing to AF lead to a significant interindividual variability in patients presenting with this arrhythmia. Regarding successful AF therapy it seems therefore reasonable to choose that treatment regimen which seems to be most suitable for the individual patient. With reports on the predictive role of atrial fibrillatory rate for sinus rhythm conversion after medical AF treatment assessment of atrial remodelling came into focus in clinical medicine.[48,49] Using various techniques for assessing electrical, contractile, and structural alterations in different types of AF the role of atrial remodelling for AF treatment became clearer (Table 2).

Table 2. Reports On Role of Atrial Remodelling in AF Treatment.

AF Treatment Remodeling Type of AF
Paroxysmal Persistent longstanding Persistent
Pharmacologic cardioversion electrical
contractile
structural
  • [48-51]

  • -

  • [49, 53]

  • [48-51]

  • [52]

  • [49, 53]

-
-
-
Electrical cardioversion electrical
contractile
structural
  • -

  • -

  • [53]

  • [54, 55]

  • [52, 56]

  • [53, 55]

-
-
-
Catheter ablation electrical
contractile
structural
  • -

  • [57]

  • [59-63, 64]

  • -

  • [57, 58]

  • [59, 60, 62, 64]

  • -

  • [58]

  • [60]

Surgical ablation electrical
contractile
structural
  • -

  • -

  • [10, 65]

  • -

  • -

  • [10, 65, 66]

  • -

  • [28]*

  • [10, 28]

Pharmacologic cardioversion electrical
contractile
structural
  • -

  • -

  • [67]

  • -

  • -

  • [67]

  • -

  • -

  • [67]

* univariate Analysis

The Role of Electrical Remodeling

Initially, electrical remodelling was investigated using high-gain, high-resolution surface ECG for analysing atrial fibrillatory activity.[48,49,68] It was shown that atrial fibrillatory frequency predicted sinus rhythm conversion after treatment of early types of the arrhythmia, mainly paroxysmal or shortstanding persistent AF, with antiarrhythmic drugs.[48,49] For treatment of longstanding persistent AF by surgical ablation, these parameters did not play any relevant role.[28] Regarding DF and CFAE as signs of electrical remodelling, there is evidence, that catheter ablation at these sites in patients with paroxysmal and persistent AF supports AF termination and prevent AF inducibility.[21,69] Nevertheless, for ablative and surgical AF treatment, it seems obvious that the longer AF persists, the more important becomes (contractile and) structural remodelling (Table 2).

The Role of Contractile Remodelling

Contractile remodelling usually assessed by echocardiographic parameters plays a role most notably for pharmacological and electrical cardioversion and ablation of early AF types.[52,56,57]It seems to be less important for surgical ablation of longstanding AF, although we could demonstrate a weak trend in univariate analysis toward better atrial contractility in patients who regained sinus rhythm after AF ablation and mitral valve surgery.[28] At least two reports on catheter ablation of paroxysmal and persistent AF suggest that left atrial function assessed by 2D speckle tracking before ablation or by intracardiac Doppler measurement after ablation predicts AF recurrence.[57,58]

The Role of Structural Remodelling

Several studies (Table 2) have demonstrated, that structural remodelling plays the most prominent role for rhythm outcome after AF treatment. Left atrial dilatation, precisely assessed as left atrial volume by multi-slice CT imaging, is one of the strongest predictors of rhythm outcome following AF ablation.[64,70] Patients with left atrial volume greater than 135 ml are likely to develop recurrent AF after catheter ablation.[64] For practical reasons, echocardiographic measurement of the end-systolic left atrial dimension in the parasternal long axis view is widely used to determine the eligibility for AF ablation with cut-offs of 5 or 5.5 cm, although this parameter correlates poorly with true left atrial volume.[13,70] For surgical AF treatment, either by ablation or by cut-and-sew maze procedure, left atrial size was also demonstrated to be an important predictor for AF recurrence.[3,28,66,67] The cut-off value for left atrial size was 56.8 m for treatment of persistent AF by radiofrequency maze procedure with concomitant mitral valve surgery.[66]

As suggested by one group, visualization and quantification of atrial fibrosis by cardiac delayed enhanced magnetic resonance imaging (DE-MRI) could be useful for more individualized stratification.[62] However, further efforts are required to validate the predictive accuracy of DE-MRI-detected fibrosis in predicting outcomes of AF ablation, before this elaborate technique should be introduced into clinical routine.

According to experimental data, beneficial effects of pharmacological therapy by ACE inhibitors, angiotensin receptor blockers (ARBs), and aldosterone receptor antagonists on structural remodelling could be expected, especially by antifibrotic effects.[14,71] Although supported by previous clinical trial data,[7274] this concept of renin-angiotensin system inhibition for so-called upstream therapy has failed to demonstrate convincing clinical results regarding the burden of AF and changes in left atrial dimensions in recent randomized controlled trials.[75,76] Now, there is very little reason to consider such therapy in patients with less or no structural heart disease .[15] However, the impact of upstream therapy on atrial fibrosis in AF patients undergoing ablative treatment needs further clarification.

Conclusions for AF Ablation

Today, AF treatment by catheter ablation is clearly indicated (class I, level A) in symptomatic patients with paroxysmal AF refractory or intolerant to antiarrhythmic drug therapy.[13,15] Furthermore,catheter ablation is reasonable (class IIa, level B) in (1) symptomatic patients with persistent AF refractory or intolerant to antiarrhythmic drug therapy and (2) in selected patients with symptomatic paroxysmal AF as first-line treatment, when patient choice, benefit, and risk are considered.[13,15] AF treatment by concomitant surgical ablation is reasonable (class IIa, level C) in (1) symptomatic patients with all types of AF refractory or intolerant to antiarrhythmic drug therapy and in (2) symptomatic patients with paroxysmal or persistent AF prior to initiation of antiarrhythmic drug therapy.[13]

Despite these clear indications for AF ablation, evaluation of potential benefits and risks of procedural failure or complications is necessary for individual decision making. Predictors of rhythm outcome may help to stratify treatment options. Remodelling parameters which have been demonstrated to predict rhythm outcome after surgical or catheter ablation and techniques for their assessment are summarized in Table 3. There is consensus, that patients with advanced remodelling need to be adequately counselled on their higher risk of treatment failure. In this group it is necessary to perform more extensive ablation and/or to do a more aggressive LA reduction in patients undergoing cardiac surgery.[10,60,62] However, as long as the value of these additional procedures is indefinite we should be cautious adding something if there is any chance that it might increase periprocedural risk. Furthermore, the data published so far are not sufficient to determine general thresholds of remodelling parameters. Thus, appropriate cut-off values – with special regards to structural remodelling - should be defined and proved based on particular local conditions (patient cohorts, ablation procedures, experience, results, follow up, etc.).

Table 3. Remodelling Parameters as Predictors for Rhythm Outcome After Ablation of Different AF Types and Techniques for Their Assessment.

Technique Parameter Reference Type of AF
Paroxysmal Persistent Long-Standing Persistent
Echocardiography LA Diameter [59]
(TTE, TEE) [10]
[66]
LA Volume [63]
LA Strain [57]
Computed Tomography LA Volume [60]
(MDCT) [64]
[61]
RA Volume [61]
Magnet Resonance Imaging LA Volume [62]
(DE-MRI) LA Fibrosis [62]
TTE, transthoracic echocardiography, TEE, transesophageal echocardiography, MDCT, multi-detector computed tomography, DE-MRI, delayed enhanced magnetic resonance imaging, LA, left atrial, RA, right atrial, light grey, catheter ablation, dark grey, surgical ablation

Summary

There have been considerable advances in under standing the relationship of AF and atrial remodelling and its impact on the progressive course of this arrhythmia. Moreover, recognizing parameters of remodelling as predictors for AF treatment – in particular the role of structural remodelling for AF ablation – helps us (1) to differentiate between patients who may or not benefit from the procedure and (2) to individualize AF treatment by adapting lesion sets, ablate additional targets, reduce left atrial size, or apply extended pharmacological treatment targeting reverse remodelling. However, for individual decision making there is urgent need for further clinical studies defining appropriate cut-off values of structural remodelling and testing the efficacy of accordingly adapted treatment strategies.

Disclosures

No disclosures relevant to this article were made by the authors.

References

  • 1.Fuster Valentin, Rydén Lars E, Cannom David S, Crijns Harry J, Curtis Anne B, Ellenbogen Kenneth A, Halperin Jonathan L, Le Heuzey Jean-Yves, Kay G Neal, Lowe James E, Olsson S Bertil, Prystowsky Eric N, Tamargo Juan Luis, Wann Samuel, Smith Sidney C, Jacobs Alice K, Adams Cynthia D, Anderson Jeffery L, Antman Elliott M, Halperin Jonathan L, Hunt Sharon Ann, Nishimura Rick, Ornato Joseph P, Page Richard L, Riegel Barbara, Priori Silvia G, Blanc Jean-Jacques, Budaj Andrzej, Camm A John, Dean Veronica, Deckers Jaap W, Despres Catherine, Dickstein Kenneth, Lekakis John, McGregor Keith, Metra Marco, Morais Joao, Osterspey Ady, Tamargo Juan Luis, Zamorano José Luis. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace. 2006 Sep;8 (9):651–745. doi: 10.1093/europace/eul097. [DOI] [PubMed] [Google Scholar]
  • 2.Kannel W B, Wolf P A, Benjamin E J, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am. J. Cardiol. 1998 Oct 16;82 (8A):2N–9N. doi: 10.1016/s0002-9149(98)00583-9. [DOI] [PubMed] [Google Scholar]
  • 3.Heeringa Jan, van der Kuip Deirdre A M, Hofman Albert, Kors Jan A, van Herpen Gerard, Stricker Bruno H Ch, Stijnen Theo, Lip Gregory Y H, Witteman Jacqueline C M. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur. Heart J. 2006 Apr;27 (8):949–53. doi: 10.1093/eurheartj/ehi825. [DOI] [PubMed] [Google Scholar]
  • 4.Wolf P A, Abbott R D, Kannel W B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991 Aug;22 (8):983–8. doi: 10.1161/01.str.22.8.983. [DOI] [PubMed] [Google Scholar]
  • 5.Gottdiener J S, Arnold A M, Aurigemma G P, Polak J F, Tracy R P, Kitzman D W, Gardin J M, Rutledge J E, Boineau R C. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J. Am. Coll. Cardiol. 2000 May;35 (6):1628–37. doi: 10.1016/s0735-1097(00)00582-9. [DOI] [PubMed] [Google Scholar]
  • 6.Benjamin E J, Wolf P A, D'Agostino R B, Silbershatz H, Kannel W B, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998 Sep 08;98 (10):946–52. doi: 10.1161/01.cir.98.10.946. [DOI] [PubMed] [Google Scholar]
  • 7.Barnett Scott D, Ad Niv. Surgical ablation as treatment for the elimination of atrial fibrillation: a meta-analysis. J. Thorac. Cardiovasc. Surg. 2006 May;131 (5):1029–35. doi: 10.1016/j.jtcvs.2005.10.020. [DOI] [PubMed] [Google Scholar]
  • 8.Cappato Riccardo, Calkins Hugh, Chen Shih-Ann, Davies Wyn, Iesaka Yoshito, Kalman Jonathan, Kim You-Ho, Klein George, Natale Andrea, Packer Douglas, Skanes Allan, Ambrogi Federico, Biganzoli Elia. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010 Feb;3 (1):32–8. doi: 10.1161/CIRCEP.109.859116. [DOI] [PubMed] [Google Scholar]
  • 9.Bonanno Carlo, Paccanaro Mariemma, La Vecchia Luigi, Ometto Renato, Fontanelli Alessandro. Efficacy and safety of catheter ablation versus antiarrhythmic drugs for atrial fibrillation: a meta-analysis of randomized trials. J Cardiovasc Med (Hagerstown) 2010 Jun;11 (6):408–18. doi: 10.2459/JCM.0b013e328332e926. [DOI] [PubMed] [Google Scholar]
  • 10.Damiano Ralph J, Schwartz Forrest H, Bailey Marci S, Maniar Hersh S, Munfakh Nabil A, Moon Marc R, Schuessler Richard B. The Cox maze IV procedure: predictors of late recurrence. J. Thorac. Cardiovasc. Surg. 2011 Jan;141 (1):113–21. doi: 10.1016/j.jtcvs.2010.08.067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Allessie Maurits, Ausma Jannie, Schotten Ulrich. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc. Res. 2002 May;54 (2):230–46. doi: 10.1016/s0008-6363(02)00258-4. [DOI] [PubMed] [Google Scholar]
  • 12.Wann L Samuel, Curtis Anne B, January Craig T, Ellenbogen Kenneth A, Lowe James E, Estes N A Mark, Page Richard L, Ezekowitz Michael D, Slotwiner David J, Jackman Warren M, Stevenson William G, Tracy Cynthia M, Fuster Valentin, Rydén Lars E, Cannom David S, Le Heuzey Jean-Yves, Crijns Harry J, Lowe James E, Curtis Anne B, Olsson S Bertil, Ellenbogen Kenneth A, Prystowsky Eric N, Halperin Jonathan L, Tamargo Juan Luis, Kay G Neal, Wann L Samuel, Jacobs Alice K, Anderson Jeffrey L, Albert Nancy, Hochman Judith S, Buller Christopher E, Kushner Frederick G, Creager Mark A, Ohman Erik Magnus, Ettinger Steven M, Stevenson William G, Guyton Robert A, Tarkington Lynn G, Halperin Jonathan L, Yancy Clyde W. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Heart Rhythm. 2011 Jan;8 (1):157–76. doi: 10.1016/j.hrthm.2010.11.047. [DOI] [PubMed] [Google Scholar]
  • 13.Calkins Hugh, Kuck Karl Heinz, Cappato Riccardo, Brugada Josep, Camm A John, Chen Shih-Ann, Crijns Harry J G, Damiano Ralph J, Davies D Wyn, DiMarco John, Edgerton James, Ellenbogen Kenneth, Ezekowitz Michael D, Haines David E, Haissaguerre Michel, Hindricks Gerhard, Iesaka Yoshito, Jackman Warren, Jalife Jose, Jais Pierre, Kalman Jonathan, Keane David, Kim Young-Hoon, Kirchhof Paulus, Klein George, Kottkamp Hans, Kumagai Koichiro, Lindsay Bruce D, Mansour Moussa, Marchlinski Francis E, McCarthy Patrick M, Mont J Lluis, Morady Fred, Nademanee Koonlawee, Nakagawa Hiroshi, Natale Andrea, Nattel Stanley, Packer Douglas L, Pappone Carlo, Prystowsky Eric, Raviele Antonio, Reddy Vivek, Ruskin Jeremy N, Shemin Richard J, Tsao Hsuan-Ming, Wilber David. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012 Apr;14 (4):528–606. doi: 10.1093/europace/eus027. [DOI] [PubMed] [Google Scholar]
  • 14.Camm A John, Kirchhof Paulus, Lip Gregory Y H, Schotten Ulrich, Savelieva Irene, Ernst Sabine, Van Gelder Isabelle C, Al-Attar Nawwar, Hindricks Gerhard, Prendergast Bernard, Heidbuchel Hein, Alfieri Ottavio, Angelini Annalisa, Atar Dan, Colonna Paolo, De Caterina Raffaele, De Sutter Johan, Goette Andreas, Gorenek Bulent, Heldal Magnus, Hohloser Stefan H, Kolh Philippe, Le Heuzey Jean-Yves, Ponikowski Piotr, Rutten Frans H. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010 Oct;12 (10):1360–420. doi: 10.1093/europace/euq350. [DOI] [PubMed] [Google Scholar]
  • 15.Camm A John, Lip Gregory Y H, De Caterina Raffaele, Savelieva Irene, Atar Dan, Hohnloser Stefan H, Hindricks Gerhard, Kirchhof Paulus. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 2012 Nov;33 (21):2719–47. doi: 10.1093/eurheartj/ehs253. [DOI] [PubMed] [Google Scholar]
  • 16.Nattel Stanley. New ideas about atrial fibrillation 50 years on. Nature. 2002 Jan 10;415 (6868):219–26. doi: 10.1038/415219a. [DOI] [PubMed] [Google Scholar]
  • 17.Schotten Ulrich, Verheule Sander, Kirchhof Paulus, Goette Andreas. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol. Rev. 2011 Jan;91 (1):265–325. doi: 10.1152/physrev.00031.2009. [DOI] [PubMed] [Google Scholar]
  • 18.Haïssaguerre M, Jaïs P, Shah D C, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. 1998 Sep 03;339 (10):659–66. doi: 10.1056/NEJM199809033391003. [DOI] [PubMed] [Google Scholar]
  • 19.Allessie M A, Boyden P A, Camm A J, Kléber A G, Lab M J, Legato M J, Rosen M R, Schwartz P J, Spooner P M, Van Wagoner D R, Waldo A L. Pathophysiology and prevention of atrial fibrillation. Circulation. 2001 Feb 06;103 (5):769–77. doi: 10.1161/01.cir.103.5.769. [DOI] [PubMed] [Google Scholar]
  • 20.Schmitt Claus, Ndrepepa Gjin, Weber Stefan, Schmieder Sebastian, Weyerbrock Sonja, Schneider Michael, Karch Martin R, Deisenhofer Isabel, Schreieck Jürgen, Zrenner Bernhard, Schömig Albert. Biatrial multisite mapping of atrial premature complexes triggering onset of atrial fibrillation. Am. J. Cardiol. 2002 Jun 15;89 (12):1381–7. doi: 10.1016/s0002-9149(02)02350-0. [DOI] [PubMed] [Google Scholar]
  • 21.Sanders Prashanthan, Berenfeld Omer, Hocini Mélèze, Jaïs Pierre, Vaidyanathan Ravi, Hsu Li-Fern, Garrigue Stéphane, Takahashi Yoshihide, Rotter Martin, Sacher Fréderic, Scavée Christophe, Ploutz-Snyder Robert, Jalife José, Haïssaguerre Michel. Spectral analysis identifies sites of high-frequency activity maintaining atrial fibrillation in humans. Circulation. 2005 Aug 09;112 (6):789–97. doi: 10.1161/CIRCULATIONAHA.104.517011. [DOI] [PubMed] [Google Scholar]
  • 22.Bosch R F, Zeng X, Grammer J B, Popovic K, Mewis C, Kühlkamp V. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc. Res. 1999 Oct;44 (1):121–31. doi: 10.1016/s0008-6363(99)00178-9. [DOI] [PubMed] [Google Scholar]
  • 23.Workman A J, Kane K A, Rankin A C. The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation. Cardiovasc. Res. 2001 Nov;52 (2):226–35. doi: 10.1016/s0008-6363(01)00380-7. [DOI] [PubMed] [Google Scholar]
  • 24.Bollmann A, Sonne K, Esperer H D, Toepffer I, Langberg J J, Klein H U. Non-invasive assessment of fibrillatory activity in patients with paroxysmal and persistent atrial fibrillation using the Holter ECG. Cardiovasc. Res. 1999 Oct;44 (1):60–6. doi: 10.1016/s0008-6363(99)00156-x. [DOI] [PubMed] [Google Scholar]
  • 25.Attuel P, Childers R, Cauchemez B, Poveda J, Mugica J, Coumel P. Failure in the rate adaptation of the atrial refractory period: its relationship to vulnerability. Int. J. Cardiol. 1982;2 (2):179–97. doi: 10.1016/0167-5273(82)90032-8. [DOI] [PubMed] [Google Scholar]
  • 26.Franz M R, Karasik P L, Li C, Moubarak J, Chavez M. Electrical remodeling of the human atrium: similar effects in patients with chronic atrial fibrillation and atrial flutter. J. Am. Coll. Cardiol. 1997 Dec;30 (7):1785–92. doi: 10.1016/s0735-1097(97)00385-9. [DOI] [PubMed] [Google Scholar]
  • 27.Schotten U, Ausma J, Stellbrink C, Sabatschus I, Vogel M, Frechen D, Schoendube F, Hanrath P, Allessie M A. Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation. 2001 Feb 06;103 (5):691–8. doi: 10.1161/01.cir.103.5.691. [DOI] [PubMed] [Google Scholar]
  • 28.Grubitzsch Herko, Menes Alexandro, Modersohn Diethelm, Konertz Wolfgang. The role of atrial remodeling for ablation of atrial fibrillation. Ann. Thorac. Surg. 2008 Feb;85 (2):474–80. doi: 10.1016/j.athoracsur.2007.09.047. [DOI] [PubMed] [Google Scholar]
  • 29.Inaba Yoshie, Yuda Satoshi, Kobayashi Naoko, Hashimoto Akiyoshi, Uno Kikuya, Nakata Tomoaki, Tsuchihashi Kazufumi, Miura Tetsuji, Ura Nobuyuki, Shimamoto Kazuaki. Strain rate imaging for noninvasive functional quantification of the left atrium: comparative studies in controls and patients with atrial fibrillation. J Am Soc Echocardiogr. 2005 Jul;18 (7):729–36. doi: 10.1016/j.echo.2004.12.005. [DOI] [PubMed] [Google Scholar]
  • 30.Becker Anton E. How structurally normal are human atria in patients with atrial fibrillation? Heart Rhythm. 2004 Nov;1 (5):627–31. doi: 10.1016/j.hrthm.2004.09.009. [DOI] [PubMed] [Google Scholar]
  • 31.Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo M A, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997 Aug 19;96 (4):1180–4. doi: 10.1161/01.cir.96.4.1180. [DOI] [PubMed] [Google Scholar]
  • 32.Kostin Sawa, Klein Gabi, Szalay Zoltan, Hein Stefan, Bauer Erwin P, Schaper Jutta. Structural correlate of atrial fibrillation in human patients. Cardiovasc. Res. 2002 May;54 (2):361–79. doi: 10.1016/s0008-6363(02)00273-0. [DOI] [PubMed] [Google Scholar]
  • 33.Boldt A, Wetzel U, Lauschke J, Weigl J, Gummert J, Hindricks G, Kottkamp H, Dhein S. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart. 2004 Apr;90 (4):400–5. doi: 10.1136/hrt.2003.015347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Röcken Christoph, Peters Brigitte, Juenemann Gina, Saeger Wolfgang, Klein Helmut U, Huth Christof, Roessner Albert, Goette Andreas. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation. 2002 Oct 15;106 (16):2091–7. doi: 10.1161/01.cir.0000034511.06350.df. [DOI] [PubMed] [Google Scholar]
  • 35.Le Grand B L, Hatem S, Deroubaix E, Couétil J P, Coraboeuf E. Depressed transient outward and calcium currents in dilated human atria. Cardiovasc. Res. 1994 Apr;28 (4):548–56. doi: 10.1093/cvr/28.4.548. [DOI] [PubMed] [Google Scholar]
  • 36.Corradi Domenico, Callegari Sergio, Benussi Stefano, Nascimbene Simona, Pastori Paolo, Calvi Simone, Maestri Roberta, Astorri Ettore, Pappone Carlo, Alfieri Ottavio. Regional left atrial interstitial remodeling in patients with chronic atrial fibrillation undergoing mitral-valve surgery. Virchows Arch. 2004 Nov;445 (5):498–505. doi: 10.1007/s00428-004-1040-2. [DOI] [PubMed] [Google Scholar]
  • 37.Anné Wim, Willems Rik, Roskams Tania, Sergeant Paul, Herijgers Paul, Holemans Patricia, Ector Hugo, Heidbüchel Hein. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. Cardiovasc. Res. 2005 Sep 01;67 (4):655–66. doi: 10.1016/j.cardiores.2005.04.016. [DOI] [PubMed] [Google Scholar]
  • 38.Wongcharoen Wanwarang, Chen Yao-Chang, Chen Yi-Jen, Chen Szu-Ying, Yeh Huang-I, Lin Cheng-I, Chen Shih-Ann. Aging increases pulmonary veins arrhythmogenesis and susceptibility to calcium regulation agents. Heart Rhythm. 2007 Oct;4 (10):1338–49. doi: 10.1016/j.hrthm.2007.06.023. [DOI] [PubMed] [Google Scholar]
  • 39.Pan Nan-Hung, Tsao Hsuan-Ming, Chang Nen-Chung, Chen Yi-Jen, Chen Shih-Ann. Aging dilates atrium and pulmonary veins: implications for the genesis of atrial fibrillation. Chest. 2008 Jan;133 (1):190–6. doi: 10.1378/chest.07-1769. [DOI] [PubMed] [Google Scholar]
  • 40.Goette Andreas, Juenemann Gina, Peters Brigitte, Klein Helmut U, Roessner Albert, Huth Christof, Röcken Christoph. Determinants and consequences of atrial fibrosis in patients undergoing open heart surgery. Cardiovasc. Res. 2002 May;54 (2):390–6. doi: 10.1016/s0008-6363(02)00251-1. [DOI] [PubMed] [Google Scholar]
  • 41.Schotten Ulrich, Duytschaever Mattias, Ausma Jannie, Eijsbouts Sabine, Neuberger Hans-Ruprecht, Allessie Maurits. Electrical and contractile remodeling during the first days of atrial fibrillation go hand in hand. Circulation. 2003 Mar 18;107 (10):1433–9. doi: 10.1161/01.cir.0000055314.10801.4f. [DOI] [PubMed] [Google Scholar]
  • 42.Schotten Ulrich, de Haan Sunniva, Neuberger Hans-Ruprecht, Eijsbouts Sabine, Blaauw Yuri, Tieleman Robert, Allessie Maurits. Loss of atrial contractility is primary cause of atrial dilatation during first days of atrial fibrillation. Am. J. Physiol. Heart Circ. Physiol. 2004 Nov;287 (5):H2324–31. doi: 10.1152/ajpheart.00581.2004. [DOI] [PubMed] [Google Scholar]
  • 43.Corradi Domenico, Callegari Sergio, Maestri Roberta, Benussi Stefano, Alfieri Ottavio. Structural remodeling in atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2008 Dec;5 (12):782–96. doi: 10.1038/ncpcardio1370. [DOI] [PubMed] [Google Scholar]
  • 44.Dibs Samer R, Ng Jason, Arora Rishi, Passman Rod S, Kadish Alan H, Goldberger Jeffrey J. Spatiotemporal characterization of atrial activation in persistent human atrial fibrillation: multisite electrogram analysis and surface electrocardiographic correlations--a pilot study. Heart Rhythm. 2008 May;5 (5):686–93. doi: 10.1016/j.hrthm.2008.01.027. [DOI] [PubMed] [Google Scholar]
  • 45.Yu W C, Lee S H, Tai C T, Tsai C F, Hsieh M H, Chen C C, Ding Y A, Chang M S, Chen S A. Reversal of atrial electrical remodeling following cardioversion of long-standing atrial fibrillation in man. Cardiovasc. Res. 1999 May;42 (2):470–6. doi: 10.1016/s0008-6363(99)00030-9. [DOI] [PubMed] [Google Scholar]
  • 46.Manning W J, Silverman D I, Katz S E, Riley M F, Come P C, Doherty R M, Munson J T, Douglas P S. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J. Am. Coll. Cardiol. 1994 Jun;23 (7):1535–40. doi: 10.1016/0735-1097(94)90652-1. [DOI] [PubMed] [Google Scholar]
  • 47.Ausma Jannie, van der Velden Huub M W, Lenders Marie-Hélène, van Ankeren Erwin P, Jongsma Habo J, Ramaekers Frans C S, Borgers Marcel, Allessie Maurits A. Reverse structural and gap-junctional remodeling after prolonged atrial fibrillation in the goat. Circulation. 2003 Apr 22;107 (15):2051–8. doi: 10.1161/01.CIR.0000062689.04037.3F. [DOI] [PubMed] [Google Scholar]
  • 48.Bollmann A, Kanuru N K, McTeague K K, Walter P F, DeLurgio D B, Langberg J J. Frequency analysis of human atrial fibrillation using the surface electrocardiogram and its response to ibutilide. Am. J. Cardiol. 1998 Jun 15;81 (12):1439–45. doi: 10.1016/s0002-9149(98)00210-0. [DOI] [PubMed] [Google Scholar]
  • 49.Bollmann Andreas, Binias Karl-Heinz, Toepffer Ines, Molling Jochen, Geller Christoph, Klein Helmut U. Importance of left atrial diameter and atrial fibrillatory frequency for conversion of persistent atrial fibrillation with oral flecainide. Am. J. Cardiol. 2002 Nov 01;90 (9):1011–4. doi: 10.1016/s0002-9149(02)02690-5. [DOI] [PubMed] [Google Scholar]
  • 50.Stambler B S, Wood M A, Ellenbogen K A. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy. Circulation. 1997 Dec 16;96 (12):4298–306. doi: 10.1161/01.cir.96.12.4298. [DOI] [PubMed] [Google Scholar]
  • 51.Fujiki A, Nagasawa H, Sakabe M, Sakurai K, Nishida K, Mizumaki K, Inoue H. Spectral characteristics of human atrial fibrillation waves of the right atrial free wall with respect to the duration of atrial fibrillation and effect of class I antiarrhythmic drugs. Jpn. Circ. J. 2001 Dec;65 (12):1047–51. doi: 10.1253/jcj.65.1047. [DOI] [PubMed] [Google Scholar]
  • 52.Pálinkás A, Antonielli E, Picano E, Pizzuti A, Varga A, Nyúzó B, Alegret J M, Bonzano A, Tanga M, Coppolino A, Forster T, Baralis G, Delnevo F, Csanády M. Clinical value of left atrial appendage flow velocity for predicting of cardioversion success in patients with non-valvular atrial fibrillation. Eur. Heart J. 2001 Dec;22 (23):2201–8. doi: 10.1053/euhj.2001.2891. [DOI] [PubMed] [Google Scholar]
  • 53.Olshansky Brian, Heller Eliot N, Mitchell L Brent, Chandler Mary, Slater William, Green Martin, Brodsky Michael, Barrell Patrick, Greene H Leon. Are transthoracic echocardiographic parameters associated with atrial fibrillation recurrence or stroke? Results from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. J. Am. Coll. Cardiol. 2005 Jun 21;45 (12):2026–33. doi: 10.1016/j.jacc.2005.03.020. [DOI] [PubMed] [Google Scholar]
  • 54.Bollmann Andreas, Mende Maika, Neugebauer Annerose, Pfeiffer Dietrich. Atrial fibrillatory frequency predicts atrial defibrillation threshold and early arrhythmia recurrence in patients undergoing internal cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol. 2002 Aug;25 (8):1179–84. doi: 10.1046/j.1460-9592.2002.01179.x. [DOI] [PubMed] [Google Scholar]
  • 55.Bollmann Andreas, Husser Daniela, Steinert Reiko, Stridh Martin, Soernmo Leif, Olsson S Bertil, Polywka Daniela, Molling Jochen, Geller Christoph, Klein Helmut U. Echocardiographic and electrocardiographic predictors for atrial fibrillation recurrence following cardioversion. J. Cardiovasc. Electrophysiol. 2003 Oct;14 (10 Suppl):S162–5. doi: 10.1046/j.1540.8167.90306.x. [DOI] [PubMed] [Google Scholar]
  • 56.Di Salvo Giovanni, Caso Pio, Lo Piccolo Rosalia, Fusco Angela, Martiniello Alfonso R, Russo Maria G, D'Onofrio Antonio, Severino Sergio, Calabró Paolo, Pacileo Giuseppe, Mininni Nicola, Calabró Raffaele. Atrial myocardial deformation properties predict maintenance of sinus rhythm after external cardioversion of recent-onset lone atrial fibrillation: a color Doppler myocardial imaging and transthoracic and transesophageal echocardiographic study. Circulation. 2005 Jul 19;112 (3):387–95. doi: 10.1161/CIRCULATIONAHA.104.463125. [DOI] [PubMed] [Google Scholar]
  • 57.Hammerstingl Christoph, Schwekendiek Marieke, Momcilovic Diana, Schueler Robert, Sinning Jan-Malte, Schrickel Jan W, Mittmann-Braun Erica, Nickenig Georg, Lickfett Lars. Left atrial deformation imaging with ultrasound based two-dimensional speckle-tracking predicts the rate of recurrence of paroxysmal and persistent atrial fibrillation after successful ablation procedures. J. Cardiovasc. Electrophysiol. 2012 Mar;23 (3):247–55. doi: 10.1111/j.1540-8167.2011.02177.x. [DOI] [PubMed] [Google Scholar]
  • 58.Verma Atul, Marrouche Nassir F, Yamada Hirotsugu, Grimm Richard A, Cummings Jennifer, Burkhardt J David, Kilicaslan Fethi, Bhargava Mandeep, Karim Abdul-Ahmad, Thomas James D, Natale Andrea. Usefulness of intracardiac Doppler assessment of left atrial function immediately post-pulmonary vein antrum isolation to predict short-term recurrence of atrial fibrillation. Am. J. Cardiol. 2004 Oct 01;94 (7):951–4. doi: 10.1016/j.amjcard.2004.06.039. [DOI] [PubMed] [Google Scholar]
  • 59.Pappone Carlo, Rosanio Salvatore, Augello Giuseppe, Gallus Giuseppe, Vicedomini Gabriele, Mazzone Patrizio, Gulletta Simone, Gugliotta Filippo, Pappone Alessia, Santinelli Vincenzo, Tortoriello Valter, Sala Simone, Zangrillo Alberto, Crescenzi Giuseppe, Benussi Stefano, Alfieri Ottavio. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J. Am. Coll. Cardiol. 2003 Jul 16;42 (2):185–97. doi: 10.1016/s0735-1097(03)00577-1. [DOI] [PubMed] [Google Scholar]
  • 60.Abecasis João, Dourado Raquel, Ferreira António, Saraiva Carla, Cavaco Diogo, Santos Katya Reis, Morgado Francisco Belo, Adragão Pedro, Silva Aniceto. Left atrial volume calculated by multi-detector computed tomography may predict successful pulmonary vein isolation in catheter ablation of atrial fibrillation. Europace. 2009 Oct;11 (10):1289–94. doi: 10.1093/europace/eup198. [DOI] [PubMed] [Google Scholar]
  • 61.Akutsu Yasushi, Kaneko Kyouichi, Kodama Yusuke, Suyama Jumpei, Li Hui-Ling, Hamazaki Yuji, Tanno Kaoru, Gokan Takehiko, Kobayashi Youichi. Association between left and right atrial remodeling with atrial fibrillation recurrence after pulmonary vein catheter ablation in patients with paroxysmal atrial fibrillation: a pilot study. Circ Cardiovasc Imaging. 2011 Sep;4 (5):524–31. doi: 10.1161/CIRCIMAGING.110.962761. [DOI] [PubMed] [Google Scholar]
  • 62.Akoum Nazem, Daccarett Marcos, McGann Chris, Segerson Nathan, Vergara Gaston, Kuppahally Suman, Badger Troy, Burgon Nathan, Haslam Thomas, Kholmovski Eugene, Macleod Rob, Marrouche Nassir. Atrial fibrosis helps select the appropriate patient and strategy in catheter ablation of atrial fibrillation: a DE-MRI guided approach. J. Cardiovasc. Electrophysiol. 2011 Jan;22 (1):16–22. doi: 10.1111/j.1540-8167.2010.01876.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Chao Tze-Fan, Sung Shih-Hsien, Wang Kang-Ling, Lin Yenn-Jiang, Chang Shih-Lin, Lo Li-Wei, Hu Yu-Feng, Tuan Ta-Chuan, Suenari Kazuyoshi, Li Cheng-Hung, Ueng Kuo-Chang, Wu Tsu-Juey, Chen Shih-Ann. Associations between the atrial electromechanical interval, atrial remodelling and outcome of catheter ablation in paroxysmal atrial fibrillation. Heart. 2011 Feb;97 (3):225–30. doi: 10.1136/hrt.2010.212373. [DOI] [PubMed] [Google Scholar]
  • 64.Helms Adam S, West J Jason, Patel Amit, Lipinski Michael J, Mangrum J Michael, Mounsey J Paul, Dimarco John P, Ferguson John D. Relation of left atrial volume from three-dimensional computed tomography to atrial fibrillation recurrence following ablation. Am. J. Cardiol. 2009 Apr 01;103 (7):989–93. doi: 10.1016/j.amjcard.2008.12.021. [DOI] [PubMed] [Google Scholar]
  • 65.Olasinska-Wisniewska Anna, Mularek-Kubzdela Tatiana, Grajek Stefan, Marszalek Andrzej, Sarnowski Wojciech, Jemielity Marek, Seniuk Wojciech, Lesiak Maciej, Prech Marek, Podzerek Tomasz. Impact of atrial remodeling on heart rhythm after radiofrequency ablation and mitral valve operations. Ann. Thorac. Surg. 2012 May;93 (5):1449–55. doi: 10.1016/j.athoracsur.2011.12.034. [DOI] [PubMed] [Google Scholar]
  • 66.Chen Mien-Cheng, Chang Jen-Ping, Chang Hsueh-Wen, Chen Chien-Jen, Yang Cheng-Hsu, Chen Yen-Hsun, Fu Morgan. Clinical determinants of sinus conversion by radiofrequency maze procedure for persistent atrial fibrillation in patients undergoing concomitant mitral valvular surgery. Am. J. Cardiol. 2005 Dec 01;96 (11):1553–7. doi: 10.1016/j.amjcard.2005.07.063. [DOI] [PubMed] [Google Scholar]
  • 67.Gillinov A Marc, Sirak Jon, Blackstone Eugene H, McCarthy Patrick M, Rajeswaran Jeevanantham, Pettersson Gosta, Sabik F Joseph, Svensson Lars G, Navia Jose L, Cosgrove Delos M, Marrouche Nassir, Natale Andrea. The Cox maze procedure in mitral valve disease: predictors of recurrent atrial fibrillation. J. Thorac. Cardiovasc. Surg. 2005 Dec;130 (6):1653–60. doi: 10.1016/j.jtcvs.2005.07.028. [DOI] [PubMed] [Google Scholar]
  • 68.Holm M, Pehrson S, Ingemansson M, Sörnmo L, Johansson R, Sandhall L, Sunemark M, Smideberg B, Olsson C, Olsson S B. Non-invasive assessment of the atrial cycle length during atrial fibrillation in man: introducing, validating and illustrating a new ECG method. Cardiovasc. Res. 1998 Apr;38 (1):69–81. doi: 10.1016/s0008-6363(97)00289-7. [DOI] [PubMed] [Google Scholar]
  • 69.Nademanee Koonlawee, McKenzie John, Kosar Erol, Schwab Mark, Sunsaneewitayakul Buncha, Vasavakul Thaveekiat, Khunnawat Chotikorn, Ngarmukos Tachapong. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J. Am. Coll. Cardiol. 2004 Jun 02;43 (11):2044–53. doi: 10.1016/j.jacc.2003.12.054. [DOI] [PubMed] [Google Scholar]
  • 70.Parikh Sachin S, Jons Christian, McNitt Scott, Daubert James P, Schwarz Karl Q, Hall Burr. Predictive capability of left atrial size measured by CT, TEE, and TTE for recurrence of atrial fibrillation following radiofrequency catheter ablation. Pacing Clin Electrophysiol. 2010 May;33 (5):532–40. doi: 10.1111/j.1540-8159.2010.02693.x. [DOI] [PubMed] [Google Scholar]
  • 71.Goette A, Staack T, Röcken C, Arndt M, Geller J C, Huth C, Ansorge S, Klein H U, Lendeckel U. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J. Am. Coll. Cardiol. 2000 May;35 (6):1669–77. doi: 10.1016/s0735-1097(00)00611-2. [DOI] [PubMed] [Google Scholar]
  • 72.Schneider Markus P, Hua Tsushung A, Böhm Michael, Wachtell Kristian, Kjeldsen Sverre E, Schmieder Roland E. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J. Am. Coll. Cardiol. 2010 May 25;55 (21):2299–307. doi: 10.1016/j.jacc.2010.01.043. [DOI] [PubMed] [Google Scholar]
  • 73.Savelieva Irene, Kakouros Nicholaos, Kourliouros Antonios, Camm A John. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace. 2011 Mar;13 (3):308–28. doi: 10.1093/europace/eur002. [DOI] [PubMed] [Google Scholar]
  • 74.Savelieva Irene, Kakouros Nicholaos, Kourliouros Antonios, Camm A John. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace. 2011 May;13 (5):610–25. doi: 10.1093/europace/eur023. [DOI] [PubMed] [Google Scholar]
  • 75.Goette Andreas, Schön Norbert, Kirchhof Paulus, Breithardt Günter, Fetsch Thomas, Häusler Karl Georg, Klein Helmut U, Steinbeck Gerhard, Wegscheider Karl, Meinertz Thomas. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol. 2012 Feb;5 (1):43–51. doi: 10.1161/CIRCEP.111.965178. [DOI] [PubMed] [Google Scholar]
  • 76.Yamashita Takeshi, Inoue Hiroshi, Okumura Ken, Kodama Itsuo, Aizawa Yoshifusa, Atarashi Hirotsugu, Ohe Tohru, Ohtsu Hiroshi, Kato Takao, Kamakura Shiro, Kumagai Koichiro, Kurachi Yoshihisa, Koretsune Yukihiro, Saikawa Tetsunori, Sakurai Masayuki, Sato Toshiaki, Sugi Kaoru, Nakaya Haruaki, Hirai Makoto, Hirayama Atsushi, Fukatani Masahiko, Mitamura Hideo, Yamazaki Tsutomu, Watanabe Eiichi, Ogawa Satoshi. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace. 2011 Apr;13 (4):473–9. doi: 10.1093/europace/euq439. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Atrial Fibrillation are provided here courtesy of CardioFront, LLC

RESOURCES